Setback For Autism Pioneer Seaside
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase II study testing arbaclofen for idiopathic autism showed no difference from placebo on a measure of social withdrawal but demonstrated significant improvement on disease severity and social function. That’s a hint the drug may yet be the first to affect the course of the disease and not just its symptoms – if a trial can be designed to test the right endpoint.
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.